Recent research indicates that glucagon-like peptide-1 (GLP-1) weight-loss medications may decelerate the spread of certain obesity-related cancers. The study, led by Cleveland Clinic, will be presented at the 2026 ASCO Annual Meeting in Chicago.
Research Highlights
The study involved 12,112 patients diagnosed with obesity-related cancers at stages 1 to 3. Cancer types included breast adenocarcinoma, prostate adenocarcinoma, non-small cell lung cancer (NSCLC), colorectal adenocarcinoma, hepatocellular carcinoma, renal cell carcinoma, and pancreatic adenocarcinoma.
Half of the participants began GLP-1 treatment, with medications like semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide, or pramlintide. The other half received DPP-4 inhibitor comparators, known as “gliptins.”
Significant Findings
The findings pointed to a significant reduction in cancer progression to stage 4 among those using GLP-1 drugs compared to gliptins. The risk reductions were notable for four cancer types:
- Non-small cell lung cancer: 50% reduction
- Breast cancer: 43% reduction
- Colorectal cancer: 31% reduction
- Liver cancer: 38% reduction
Dr. Mark David Orland from the Taussig Cancer Institute at Cleveland Clinic stated, “Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types.”
Further Insights
While prostate, pancreatic, and kidney cancers also showed lower spread rates among GLP-1 users, these results were not statistically significant. The study also found that tumors with higher levels of GLP-1 receptors correlated with better survival outcomes. Patients with more of these receptors were approximately one-third less likely to die during the study period.
The incidence of side effects was similar between GLP-1 and gliptin users, suggesting that the mechanism by which GLP-1 pathways influence cancer growth needs further investigation.
Research Limitations
The study, although comprehensive, has not undergone peer review. It was retrospective and observational, limiting its ability to confirm direct prevention of cancer progression by GLP-1 drugs. External factors such as participants’ health conditions and metabolic changes might have influenced the results. The need for more randomized clinical trials is emphasized to substantiate these preliminary findings and understand the methods through which GLP-1 drugs may control cancer spread.
Leave a Reply